Webinar
6 May 2022
LIVE WEBINAR > Your Injectable Roadmap: Tues Oct 13, 16:00 CEST / 10 EDT
Content provided by our supplier
Corden Pharma International GmbH
-
DE -
2015On CPHI since
-
4Certificates
-
1000 - 4999Employees
Company types
Other Content from Corden Pharma International GmbH (17)
-
News CordenPharma signs billion dollar agreement to manufacture new peptide
CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities. -
Brochure Brochure > Drug Product Services
Highlights CordenPharma's capabilities for Oral Solid Dosage and Non-Sterile Dosage forms as well as Sterile Injectable Drug Product manufacturing. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
Brochure Brochure > CordenPharma Peptides, Lipids & Carbohydrates Technology Platform
The Peptides, Lipids & Carbohydrates Platform provides you with advanced Bio-Organic APIs, including synthetic Peptides, Lipids, Carbohydrates & Conjugates, from early-stage to commercial.
-
News CPHI Frankfurt 2022: Innovator Interview – CordenPharma
In this interview from CPHI Frankfurt 2022, we speak to Dr Michael Quirmbach of CordenPharma about his role as President and CEO and what CordenPharma is bringing to the pharma industry. -
Video Video > CordenPharma Injectable Drug Product Manufacturing
Let us accompany you on your Sterile Injectable Drug Product journey under CordenPharma's Injectable Technology Platform. Our CordenPharma Caponango (IT) manufacturing facility produces liquid dosage forms with expertise in GMP Manufacturing, Aspetic Fill & Finish, Terminal Sterilization, Clinical Trials, and Pharma-Logistics. -
News Press Release > CordenPharma Colorado Expands Lipid Excipients Purification
Luxembourg, 19 April 2021 -- In response to the COVID-19 pandemic, mRNA (messenger RNA) vaccines have catapulted to center stage of the pharmaceutical and biotechnology industry. As of early 2021, there are eight ongoing human trials for mRNA vaccines led by Moderna, BioNTech / Pfizer, CureVac, Sanofi / TranslateBio, Arcturus / Duke-NUS Medical School (Singapore), Imperial College London, Chulalongkorn University (Thailand), and Providence Therapeutics. -
Video Video > CordenPharma Highly Potent API Manufacturing
CordenPharma is your partner of choice in the development and manufacturing of Highly Potent APIs. Our facilities in Boulder, CO (USA) offer API synthesis from early clinical to commercial supply. -
News Top 5 Industry Content Reads on CPHI Online This Month
If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.
-
Brochure Brochure > CordenPharma Highly Potent & Oncology Technology Platform
The Highly Potent & Oncology Platform supports your project from clinical through commercial with the development & production of highly potent APIs, Oral Solid Dosage Forms & Injectable Drug Products including ready-for-market packaging, labeling & serialization.
-
News Press Release > Pandemic Preparedness: WACKER & CordenPharma Will Produce mRNA Vaccines for Germany When Needed
11 April 2022 - Munich / Halle / Plankstadt- WACKER AND CORDENPHARMA TO BECOME PART OF GERMANY’S PANDEMIC PREPAREDNESS PLANTHE TWO COMPANIES WILL BE READY TO PRODUCE MRNA VACCINES FOR THE GERMAN GOVERNMENT IF THE COVID-19 PANDEMIC CONTINUES OR A NEW PANDEMIC OCCURS
- WACKER AND CORDENPHARMA JOINTLY COVER THE ENTIRE MANUFACTURING CHAIN FOR VACCINES
- HALLE WILL BECOME A COMPETENCE CENTER FOR PRODUCING MRNA VACCINES, WITH ADDITIONAL CAPACITY FOR OTHER CUSTOMERS AS WELL
- CORDENPHARMA WILL USE ITS YEARS OF EXPERIENCE IN PRODUCING CUSTOM AND STANDARD LIPIDS AND IN FILL & FINISH
- WACKER INTENDS TO INVEST OVER €80 MILLION ANNUALLY IN EXPANDING THE GROWTH OF ITS BIOTECHNOLOGY BUSINESS OVER THE NEXT FEW YEARS
-
Brochure Brochure > CordenPharma Injectables Technology Platform
Our Injectables Platform offers you a broad spectrum of injectable services starting from early-formulation development to full commercial scale, covering both terminal sterilization & aseptic filling. Packaging, labeling & clinical trial kit management round off this service.
-
.jpg)
News Press Release > CordenPharma & Moderna Extend Lipid Supply Agreement for Moderna’s (mRNA-1273) Vaccine Candidate
Luxembourg, 28 May 2020 -- CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) for the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the signing of an amendment to their existing manufacturing agreement with Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. -
Brochure Brochure > CordenPharma Small Molecules Technology Platform
Under the Small Molecules Platform we develop and advance your project through all phases to commercial, from advanced intermediates to drug products, from kilogram to multi-ton production volumes annually.
-
Video White Paper > Battling Counterfeit Medicine Through Packaging Serialization
Download this CordenPharma White Paper Below > Get informed about packaging serialization regulatory requirements & deadlines for global markets in this CordenPharma white paper discussing keys to combating the worldwide drug counterfeiting problem. Topics include serialization techniques in the supply chain such as Microscopic RFID Tags, Security Labels, Invisible Inks, and Track-and-Trace Technologies, and a GS1 standard language called Electronic Product Code Information Services (EPCIS). Learn the importance and benefits of choosing the right CMO or CDMO to ensure the utmost level of support in keeping patients safe. -
Video Webinar On Demand > Critical Aspects of a Robust Highly Potent Compound Program > The Importance of Understanding Intangible Elements of Containment
Register for this Live (4-4-18) or on Demand webinar to learn how the most important (and often over-looked) aspect to a robust containment program is the strength of the intangible, softer elements. Discuss how to maximize the success of your engineering control investments and allow for continued alignment to your company’s commitment to providing a workplace free of recognized health & safety hazards. -
Video Webinar On Demand > From Market Compliance to Business Supply: The Necessity for Serialization
This recorded webinar archive addresses the necessity of serialization from market compliance to business supply. Expert speaker Mario Scigliano covers all aspects of serialization, from line choice and regulation approach to management of data and related products.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance